ECSP10010153A - Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos - Google Patents

Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos

Info

Publication number
ECSP10010153A
ECSP10010153A EC2010010153A ECSP10010153A ECSP10010153A EC SP10010153 A ECSP10010153 A EC SP10010153A EC 2010010153 A EC2010010153 A EC 2010010153A EC SP10010153 A ECSP10010153 A EC SP10010153A EC SP10010153 A ECSP10010153 A EC SP10010153A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
compositions containing
bradiquinine
antagonists
hialuronic acid
Prior art date
Application number
EC2010010153A
Other languages
English (en)
Inventor
Sandro Giuliani
Carlo Alberto Maggi
Laura Quartara
Original Assignee
Luso Farmaco Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luso Farmaco Inst filed Critical Luso Farmaco Inst
Publication of ECSP10010153A publication Critical patent/ECSP10010153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se describen las composiciones farmacéuticas que contienen, como ingredientes activos, una mezcla de un polímero de ácido hialurónico con un antagonista del receptor de bradiquinina B2. Se ha comprobado que dichas composiciones son especialmente efectivas en el tratamiento de enfermedades articulares degenerativas tales como osteoartritis usando inyecciones intraarticulares.
EC2010010153A 2007-11-23 2010-05-05 Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos ECSP10010153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002225A ITMI20072225A1 (it) 2007-11-23 2007-11-23 "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
PCT/EP2008/009451 WO2009065507A2 (en) 2007-11-23 2008-11-10 Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof

Publications (1)

Publication Number Publication Date
ECSP10010153A true ECSP10010153A (es) 2010-06-29

Family

ID=40314753

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010153A ECSP10010153A (es) 2007-11-23 2010-05-05 Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos

Country Status (40)

Country Link
US (1) US9101627B2 (es)
EP (1) EP2222275B1 (es)
JP (1) JP5383695B2 (es)
KR (1) KR101585868B1 (es)
CN (1) CN101868225B (es)
AP (1) AP2628A (es)
AR (1) AR069407A1 (es)
AT (1) ATE529096T1 (es)
AU (1) AU2008328311B2 (es)
BR (1) BRPI0820402A2 (es)
CA (1) CA2706398C (es)
CL (1) CL2008003475A1 (es)
CO (1) CO6270301A2 (es)
CR (1) CR11457A (es)
CY (1) CY1112134T1 (es)
DK (1) DK2222275T3 (es)
EA (1) EA017626B1 (es)
EC (1) ECSP10010153A (es)
ES (1) ES2374861T3 (es)
GE (1) GEP20125602B (es)
HN (1) HN2010001037A (es)
HR (1) HRP20110904T1 (es)
IL (1) IL205860A (es)
IT (1) ITMI20072225A1 (es)
MA (1) MA31913B1 (es)
MX (1) MX2010005484A (es)
MY (1) MY148685A (es)
NI (1) NI201000087A (es)
NZ (1) NZ585514A (es)
PA (1) PA8804801A1 (es)
PE (1) PE20091422A1 (es)
PL (1) PL2222275T3 (es)
PT (1) PT2222275E (es)
RS (1) RS52045B (es)
SI (1) SI2222275T1 (es)
TN (1) TN2010000215A1 (es)
TW (1) TWI448292B (es)
UA (1) UA97867C2 (es)
WO (1) WO2009065507A2 (es)
ZA (1) ZA201003586B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL420378A1 (pl) * 2014-05-30 2017-10-23 Nataliia Mykolaivna Derkach Stabilizowany roztwór na bazie substancji czynnych, sposób otrzymywania stabilizowanego roztworu substancji czynnych, kompozycja farmaceutyczna na bazie stabilizowanego roztworu substancji czynnych (dwa warianty)
CN107106594A (zh) * 2014-12-26 2017-08-29 生化学工业株式会社 改善眼的自觉症状的制剂和方法
WO2020022791A1 (ko) 2018-07-25 2020-01-30 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN121472194A (zh) 2020-01-23 2026-02-06 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
JP7622088B2 (ja) 2020-08-07 2025-01-27 アルテオジェン・インコーポレイテッド 組換えヒアルロニダーゼの生産方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"

Also Published As

Publication number Publication date
EA017626B1 (ru) 2013-01-30
HN2010001037A (es) 2012-12-10
PL2222275T3 (pl) 2012-03-30
KR20100096106A (ko) 2010-09-01
IL205860A (en) 2013-01-31
GEP20125602B (en) 2012-08-10
CY1112134T1 (el) 2015-11-04
CN101868225B (zh) 2013-06-12
PE20091422A1 (es) 2009-10-17
TWI448292B (zh) 2014-08-11
DK2222275T3 (da) 2012-01-02
ATE529096T1 (de) 2011-11-15
MA31913B1 (fr) 2010-12-01
MX2010005484A (es) 2010-06-07
CA2706398C (en) 2016-07-05
CR11457A (es) 2010-11-05
JP5383695B2 (ja) 2014-01-08
IL205860A0 (en) 2010-11-30
PA8804801A1 (es) 2009-06-23
WO2009065507A3 (en) 2009-09-03
CO6270301A2 (es) 2011-04-20
NZ585514A (en) 2012-01-12
TN2010000215A1 (en) 2011-11-11
SI2222275T1 (sl) 2012-01-31
PT2222275E (pt) 2012-01-16
NI201000087A (es) 2011-07-18
AP2010005265A0 (en) 2010-06-30
RS52045B (sr) 2012-04-30
WO2009065507A2 (en) 2009-05-28
CA2706398A1 (en) 2009-05-28
AU2008328311B2 (en) 2013-02-28
AU2008328311A1 (en) 2009-05-28
TW200927151A (en) 2009-07-01
BRPI0820402A2 (pt) 2015-05-19
ES2374861T3 (es) 2012-02-22
MY148685A (en) 2013-05-31
CN101868225A (zh) 2010-10-20
AP2628A (en) 2013-03-26
ITMI20072225A1 (it) 2009-05-24
US20100292156A1 (en) 2010-11-18
AR069407A1 (es) 2010-01-20
US9101627B2 (en) 2015-08-11
KR101585868B1 (ko) 2016-01-22
UA97867C2 (ru) 2012-03-26
HRP20110904T1 (hr) 2011-12-31
ZA201003586B (en) 2011-08-31
JP2011504473A (ja) 2011-02-10
HK1149714A1 (en) 2011-10-14
CL2008003475A1 (es) 2009-03-27
EP2222275A2 (en) 2010-09-01
EA201000678A1 (ru) 2010-12-30
EP2222275B1 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CO6270301A2 (es) Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
IN2012DN02702A (es)
IN2012DN00754A (es)
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
BR112014012789A2 (pt) agentes terapêuticos compreendendo sequências de aminoácidos de insulina
MX357496B (es) Moduladores del receptor de estrógenos fluorados y sus usos.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.
EP2547203A4 (en) CCR5 MODULATORS TO TREAT HIV
ECSP15005163A (es) Composiciones líquidas orales pediátricas que contienen nepadutant
ECSP11010752A (es) Composiciones farmacéuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides
UY32679A (es) Antagonistas policíclicos de receptores de ácido lisofosfatidico
MX380487B (es) Fructanos de agave como excipiente farmacéutico funcional en una forma de dosificación de liberación inmediata.
EA200900172A1 (ru) Фармацевтическая композиция для контрацепции
UY36556A (es) Nuevas composiciones farmacéuticas para el tratamiento de la hipertensión
CL2011002316A1 (es) Compuestos derivados de furopirimidinona, moduladores de receptores trpa1; composicion farmaceutica; y uso en el tratamiento del dolor.